115 related articles for article (PubMed ID: 16894565)
1. Molecular determinants of irinotecan efficacy.
Vallböhmer D; Iqbal S; Yang DY; Rhodes KE; Zhang W; Gordon M; Fazzone W; Schultheis AM; Sherrod AE; Danenberg KD; Lenz HJ
Int J Cancer; 2006 Nov; 119(10):2435-42. PubMed ID: 16894565
[TBL] [Abstract][Full Text] [Related]
2. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of cetuximab efficacy.
Vallböhmer D; Zhang W; Gordon M; Yang DY; Yun J; Press OA; Rhodes KE; Sherrod AE; Iqbal S; Danenberg KD; Groshen S; Lenz HJ
J Clin Oncol; 2005 May; 23(15):3536-44. PubMed ID: 15908664
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
6. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
7. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
[TBL] [Abstract][Full Text] [Related]
8. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
10. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
11. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
13. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J; Nishina T; Yamada Y; Moriwaki T; Shimoda T; Kajiwara T; Nakajima TE; Kato K; Hamaguchi T; Shimada Y; Okayama Y; Oka T; Shirao K
Br J Cancer; 2008 Feb; 98(4):832-9. PubMed ID: 18231104
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
[TBL] [Abstract][Full Text] [Related]
15. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
Gustavsson B; Kaiser C; Carlsson G; Wettergren Y; Odin E; Lindskog EB; Niyikiza C; Ma D
Int J Cancer; 2009 Mar; 124(5):1220-6. PubMed ID: 19051292
[TBL] [Abstract][Full Text] [Related]
17. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
Ceppi P; Longo M; Volante M; Novello S; Cappia S; Bacillo E; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
J Thorac Oncol; 2008 Jun; 3(6):583-9. PubMed ID: 18520795
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
Ishida H; Shirakawa K; Ohsawa T; Hayashi Y; Okada N; Nakada H; Yokoyama M
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1295-9. PubMed ID: 16184927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
